Physician
Casamalhuapa, Martha
Casamalhuapa, Martha was paid $2.52M by Medicaid between Jan 2021 and Nov 2024, across 62 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 40% of everything it billed.
33Billing provider infoCASAMALHUAPA, MARTHA
WOODBRIDGE, VA 22193
WOODBRIDGE, VA 22193
33aNPI1912288515assigned 09/09/2011
33bProvider typePediatrics Physician
28Total paid$2.52M
24GClaims77,643
24DCodes billed62
24AFirst – last monthJan 2021 – Nov 2024
Compared with peers
Next to other Pediatrics Physician providers in Virginia
Rank by total paid#72 of 817
Median peer was paid$29K
This provider vs. median86×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2021 | 11,567 | $373K | |
| 2022 | 18,652 | $604K | |
| 2023 | 25,835 | $783K | |
| 2024incomplete | 21,589 | $761K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 40% | 16,088 | 13,254 | $1.00M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 17% | 4,923 | 4,462 | $420K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.7% | 1,859 | 1,857 | $143K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 5.3% | 1,758 | 1,753 | $134K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 4.5% | 3,711 | 3,515 | $112K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 3.8% | 3,575 | 3,381 | $95K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 3.5% | 1,251 | 1,215 | $87K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.4% | 6,284 | 5,912 | $85K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.8% | 851 | 847 | $71K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.8% | 1,369 | 1,315 | $46K |
| 99058 | 1.8% | 1,684 | 1,559 | $45K | |
| 92551 | 1.1% | 2,890 | 2,872 | $28K |
50 more codes
| 92552 | 1.1% | 884 | $27K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 1.0% | 2,866 | $25K |
| 99000 | <1% | 4,620 | $17K | |
| 90651 | <1% | 277 | $14K | |
| 90680 | <1% | 735 | $12K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 89 | $11K |
| 90633 | <1% | 770 | $10K | |
| 96127 | <1% | 1,990 | $10K | |
| 90670 | <1% | 667 | $10K | |
| 90671 | <1% | 241 | $10K | |
| 90677 | <1% | 259 | $9K | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,424 | $9K |
| 99177 | <1% | 2,208 | $9K | |
| 90698 | <1% | 894 | $8K | |
| 90744 | <1% | 605 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 82 | $6K |
| 90710 | <1% | 155 | $6K | |
| 99173 | <1% | 2,263 | $5K | |
| 99383 | <1% | 50 | $4K | |
| 99442 | <1% | 70 | $4K | |
| 90649 | <1% | 134 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 410 | $4K |
| 90686 | <1% | 252 | $3K | |
| 90620 | <1% | 83 | $3K | |
| 90658 | <1% | 302 | $3K | |
| 90461 | <1% | 2,378 | $3K | |
| 90716 | <1% | 111 | $3K | |
| 90707 | <1% | 143 | $2K | |
| 90674 | <1% | 159 | $2K | |
| 90700 | <1% | 165 | $2K | |
| 87807 | <1% | 168 | $2K | |
| 90715 | <1% | 101 | $1K | |
| 99384 | <1% | 14 | $1K | |
| 99381 | <1% | 13 | $1K | |
| 90648 | <1% | 96 | $1K | |
| 90696 | <1% | 136 | $996.93 | |
| 99402 | <1% | 23 | $852.60 | |
| A4617 | Mouth piece | <1% | 243 | $703.50 |
| A7015 | Aerosol mask, used with dme nebulizer | <1% | 412 | $510.23 |
| A7004 | Small volume nonfiltered pneumatic nebulizer, disposable | <1% | 255 | $436.75 |
| 94664 | <1% | 253 | $85.90 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 283 | $55.33 |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 32 | $6.72 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 46 | $0.10 |
| 90734 | 0% | 271 | $0.00 | |
| 91300 | 0% | 384 | $0.00 | |
| 0002A | 0% | 145 | $0.00 | |
| 99404 | 0% | 45 | $0.00 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | 0% | 16 | $0.00 |
| 0001A | 0% | 178 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.